The combination of modifications in terms of DC activation (e.g., CD40L and caTLR4), DC migration to lymph nodes (e.g., CCR7), and knockout of PDL1-driven immunosuppression could dramatically increase DC vaccine efficacy in cancer therapy. The gene discussed is CD274; the disease is cancer.